News and Events
Topics
-
Topcon Introduces TRK-3 OMNIA Auto Kerato-Refracto Tonometer to the Asian Market
Topcon Healthcare, a leading provider of medical devices andsoftware solutions for the global eye care community, is pleased toannounce the launch the TRK-3 OMNIA to the Asian Market.The TRK-3 OMNIA is a new auto kerato-refracto tonometer that will help eye care professionals optimise their clinical workflow and streamline patient care.The new TRK-3OMNIA is a 4-in-1 instrument that offers a combined refractometer, keratometer, non-contact tonometer, and pachymeter in one compact instrument. Capturing four measurements with a single device will help eye care professionals drive efficiency while improving patient comfort by eliminating the need to move between multiple devices. The TRK-3 OMNIA offers significant enhancements that build upon the strong performance of its predecessor. The quick, one-touch operation is complemented by the patented rotary prism technology that delivers stable measurements while the improved user interface elevates ease of use. The addition of DICOM enhances TRK-3 OMNIA connectivity. About Topcon Topcon’s vision is to provide healthcare professionals with intelligent, efficient technologies to improve patient care. In the fast-changing healthcare market, we offer the latest integrated solutions, including multimodal imaging, vendor-inclusive data management, and revolutionary remote diagnostic technology. Topcon Corporation strives to develop solutions tailored to the societal challenges of healthcare, agriculture, and infrastructure. In the healthcare sector, the biggest challenges are prevalence of eye diseases, access to healthcare, and the shortage of doctors. By investing in cutting-edge technologies, Topcon Corporation works to improve people’s health and quality of life. https://topconhealthcare.jp/products/trk-3-omnia/Note: The information contained on this website is intended for healthcare professionals. Not all products, services, or offers are approved or offered in every market, and products vary from one country to another. Contact your local distributor for country-specific information and availability.
-
Public statement regarding recent lawsuit settlement
Topcon Healthcare is pleased to announce we have reached a positive resolution to a lawsuit with Carl Zeiss Meditec that has been a distraction for over four years. Topcon made a strategic decision to settle ongoing litigation with Zeiss to remove the distraction and allow us to focus on our mission to serve our customers and help improve access and quality of care while reducing the overall cost of care. We are known for quality products and quality people. We intend to continue delivering value and intelligent solutions to our customers and the healthcare market. Topcon admitted no wrongdoing in the settlement. During the (4 years of) litigation almost all of Zeiss’s claims were dismissed or withdrawn. The final settlement relates to a legacy version of Harmony (which has not been actively licensed by Topcon for several years). Customers using our current product, Harmony RS, are not affected by the settlement, and none of the devices or software that we are promoting or plan to implement in the future are affected by the conditions in the settlement in any way.
-
Establishment of Topcon Korea Medical Co., Ltd.
Located in Seoul, Korea, Topcon Korea Medical Co., Ltd. (TKM) was established and formally launched in 2023. Topcon Healthcare, via TKM, will pursue better clinical processes and outcomes for customers and their patients in Korea. Topcon Corporation (HQ: Itabashi-ku, Tokyo; President: Takashi Eto) (henceforth Topcon) has established Topcon Korea Medical Co., Ltd. (HQ: Seoul, South Korea, President : Artur Chu) (henceforth TKM) to strengthen and expand its eye care business in South Korea. The company was registered in March 2023, and full-scale sales and marketing operations began in the second half of 2023 after the company's infrastructure and team staff were established.In South Korea, as in other developed countries, as the government is responding to the increase in eye disease associated with an ageing population South Korea is focusing on a strategy of early detection and treatment applied broadly across the eye care sector to meet the high and increasing demand for examination through treatment.Optical stores market in Korea is different domain. It is highly competitive. Global economy and COVID-19 affects seriously, however in accordance with increased demand for good quality lenses for myopia and presbyopia, business opportunities are recovering. TKM also is ready to contribute here to optimize the workflow and profitable management. Topcon Korea Medical is a strong partner for all eye care professionals, providing innovative products and services required by customers in the fields of optometry and ophthalmology, as well as new businesses including health check-up and screening services, to contribute to optimal patient care. Message from the president"Introducing Topcon Korea Medical Co., Ltd. Empowering Excellence in the Korean Market. With a firm foundation built on understanding the unique needs of the Korean market, TKM is poised to revolutionize the industry landscape.Our dedication to quality, innovation, and a deep cultural understanding ensures that we not only meet, but exceed the expectations of our Korean partners. Join us on this exciting journey as we redefine possibilities in Korea and beyond."Artur Chu,Learn More about Topcon korea medical
News
-
Pangaea Data Secures Strategic Investment from Topcon Healthcare, Inc. to Close Global Care Gaps in Eye Health
SOUTH SAN FRANCISCO, CA; LONDON, UK; and LA JOLLA, CA – Pangaea Data, a health AI company specializing in identifying untreated and under-treated patients at scale, today announced a strategic investment from Topcon Healthcare, Inc., a global leader in ophthalmic medical devices and digital health solutions. The collaboration aims to accelerate the application of Pangaea’s clinically validated AI platform to address critical care gaps in eye health and systemic disease.Pangaea Data’s platform automatically analyzes structured and unstructured patient records against clinical guidelines, emulating a clinician’s manual review, to uncover patients who meet diagnostic or treatment criteria, but are not currently in a treatment or management process. Integrated directly into existing EHR and downstream scheduling systems, the platform enables real-time clinical action without disrupting workflows.“We are thrilled to partner with Topcon Healthcare to scale our platform’s reach and improve timely diagnosis and treatment across eye care,” said Dr. Vibhor Gupta, Founder and CEO of Pangaea Data. “Together, we can empower providers to close care gaps while generating actionable insights for population health, discovery science, and value-based care.”Through this partnership, Pangaea Data’s AI platform will leverage Topcon Healthcare’s Harmony® digital health platform, creating a seamless interface for optometry and ophthalmology practices to identify patients needing follow-up or further evaluation. This includes patients with conditions such as glaucoma, 50% of whom remain undiagnosed in the U.S.1, and diabetic retinopathy, where more than one-third of diagnosed diabetics do not receive their recommended annual eye screening2.“Pangaea Data’s unique ability to find missed patients using AI, and to do so without burdening clinicians, has powerful implications for eye care and beyond,” said Ali Tafreshi, CEO & President of Topcon Healthcare, Inc. “This partnership supports our Healthcare from the Eye™ initiative, which uses ocular data and AI to transform how systemic and ocular diseases are detected and managed. We are proud to support Pangaea Data’s mission through this strategic investment.”Pangaea Data’s platform has already demonstrated impact across multiple therapeutic areas, including pulmonology, cardiology, oncology, nephrology, and infectious diseases. The company’s expansion into eye care through this partnership represents a significant step in advancing AI-driven clinical care globally.1 Current Glaucoma Programs | Vision and Eye Health | CDC – https://www.cdc.gov/vision-health/php/glaucoma-programs/index.html2 Diabetic Retinopathy Screening – EyeWiki – https://eyewiki.org/Diabetic_Retinopathy_ScreeningAbout Pangaea DataPangaea Data provides an AI platform that is configured on clinical guidelines to mimic and therefore automate a clinician’s manual process for finding untreated (undiagnosed, misdiagnosed, miscoded, at-risk, uncontrolled) and under-treated patients with hard-to-diagnose conditions for screening and treatment at the point of care. These patients may otherwise be missed, despite information available in their health records, due to treatment for other conditions or administrative reasons. Pangaea’s platform is designed to be deployed behind the healthcare provider’s firewall, without moving data, facilitating privacy compliance. Furthermore, the platform is designed to seamlessly integrate with existing EHR systems, avoiding disruption to existing clinical or IT workflows. Pangaea Data’s founders, Dr. Vibhor Gupta and Prof. Yike Guo, have over 20 years of academic and industry experience. Their advisors and investors include industry veterans, such as Lord David Prior (Former Chairman, NHS England) and Mr. Andy Palmer (Former Head of Systems Integration, Novartis). For more information, visit www.pangaeadata.aiAbout Topcon Healthcare, Inc.Topcon Healthcare, Inc. is part of Topcon Corporation, a leading provider of digital healthcare solutions. Our vision is to improve access and quality of healthcare while decreasing the cost of care. To achieve this vision, we created Healthcare from the Eye™, a connected care ecosystem using AI-powered disease detection and management applied to noninvasive retinal imaging.
-
Moorfields Eye Hospital, UCL Institute of Ophthalmology and Topcon Healthcare, Inc. launch Cascader Limited to advance AI-driven eyecare and Oculomics
Moorfields Eye Hospital NHS Foundation Trust, the UCL Institute of Ophthalmology (IoO), and Topcon Healthcare today announced the launch of Cascader Limited, a new medical technology company that aims to transform the detection and management of eye disease through artificial intelligence (AI). Cascader also builds on the growing field of Oculomics – the use of advanced retinal imaging to uncover insights into systemic conditions such as cardiovascular disease, neurodegeneration, and dementia.Cascader represents a strategic partnership between world-leading academic and clinical institutions and a global healthcare technology provider. The company combines the pioneering AI research and translational expertise of Moorfields and UCL IoO with the technical capabilities and international reach of Topcon Healthcare, a provider of ophthalmic imaging systems used in hospitals and community clinics around the world. UCL Business (UCLB), the commercialisation company for UCL and its partner hospitals, was also instrumental in the set-up of the new venture.Headquartered in London, Cascader is focused on accelerating the translation of cutting-edge AI from research into real-world clinical tools – so that novel diagnostic technologies can reach patients faster.Its initial focus will be on macular diseases such as age-related macular degeneration (AMD), a leading cause of irreversible vision loss that affects one in eight people over the age of 60. This builds on landmark work led by Moorfields and UCL IoO, including the 2016 collaboration with Google DeepMind and the development of RETFound, the first foundation model in ophthalmology, published in Nature in 2023.Cascader’s long-term mission is to develop a portfolio of AI tools to support earlier and more accurate detection of disease across the full spectrum of eye care – from high-street optometry to hospital-based specialist clinics – and to further advance Oculomics as a foundation for precision medicine.Cascader will be supported by the INSIGHT Health Data Research Hub, the world’s largest ophthalmic imaging bioresource, led by Moorfields. INSIGHT comprises over 35 million retinal images linked to clinical metadata and enables secure, anonymised data access for approved researchers – supported by advanced AI infrastructure, curation services, and active patient involvement.Cascader marks a significant step in translating Oculomics into clinical care and aligns with broader global efforts – including Topcon Healthcare’s Healthcare from the Eye™ initiative – to harness ocular data as a gateway to more proactive, connected, and equitable healthcare.Peter Ridley, Chief Executive of Moorfields Eye Hospital:“We are proud to support the founding of Cascader. This new venture represents the next step in our commitment to translating world-class clinical research into tangible benefits for patients and the NHS.”Ali Tafreshi, Chief Executive Officer, Topcon Healthcare:“Topcon is thrilled to partner with Moorfields and the UCL Institute of Ophthalmology on this groundbreaking initiative. Cascader reflects our shared vision of how AI and ocular data can reshape eyecare and enable new frontiers in precision medicine. This collaboration supports the broader mission of connecting ocular data to better health outcomes – both within eyecare and beyond.”Mark Fisher, Associate Director at UCLB:“UCLB is delighted to have played a role in the establishment in this new company alongside Moorfields Eye Hospital NHS Foundation Trust and Topcon Inc. Partnering with industrial leaders in the new area of oculomics should accelerate routes to market for AI technologies and break down the barriers of AI applications in healthcare. It exemplifies the benefits of close relationships between academics and clinicians in creating technologies that will bring major benefits to patients as a result of earlier diagnosis in a range of diseases.”Professor Pearse Keane, Chief Medical Advisor and co-founder of Cascader; consultant ophthalmologist at Moorfields Eye Hospital; professor of artificial medical intelligence at UCL IoO:“Cascader is uniquely positioned at the intersection of clinical excellence, academic leadership, and technological innovation. We are building on more than a decade of research into AI and Oculomics – fields in which we’ve been proud to lead globally – and are now focused on delivering those discoveries into everyday clinical care.”Dr. Peter Thomas, Chief Executive Officer and co-founder of Cascader; consultant ophthalmologist at Moorfields Eye Hospital:“We have a huge opportunity to reshape how eye care is delivered by bringing AI to frontline services – whether in hospitals, clinics, or the high street. Cascader will play a key role in translating groundbreaking research into real-world tools that support both patients and professionals.”Ege Ilicak, Chief Operating Officer and co-founder of Cascader:“At Cascader, our mission is to turn cutting-edge research into clinically robust, scalable solutions that improve lives. With deep experience in medical engineering, we’re focused on ensuring that our AI-driven tools meet the highest quality and regulatory standards, while integrating seamlessly into real-world workflows—supporting professionals and empowering patients.” For further information, please contact moorfields.pressoffice@nhs.net or Leslie Amodei at lamodei@amaeharaAbout Cascader’s founding team:Cascader’s founding team brings together deep expertise across the clinical, technical, and operational spectrum:• Professor Pearse Keane, a global leader in ophthalmic AI and Oculomics, has led pioneering research at Moorfields and UCL IoO, including co-inventing RETFound, the world’s first foundation model in ophthalmology, and extensive work defining the field of Oculomics.• Dr Peter Thomas, brings extensive experience in developing and delivering innovative healthcare services powered by technology, leading digital transformation programmes, and holding executive and national leadership roles within the NHS. • Ege Ilicak, chief operating officer, brings 15 years of experience in the medical engineering field, from hands-on software development to managing large-scale projects and building quality management systems to bring healthcare innovations successfully to market.About Moorfields Eye Hospital NHS Foundation TrustMoorfields Eye Hospital NHS Foundation Trust is one of the leading providers of eye health services in the UK and a world class centre of excellence for ophthalmic research and education. Our main focus is the treatment and care of NHS patients with a wide range of eye problems, from common complaints to rare conditions that require treatment not available elsewhere in the UK. Our unique patient case mix and the number of people we treat mean that our clinicians have expertise in discrete ophthalmic sub-specialties.We treat people in 20 locations in and around London, the south east and Bedford, enabling us to provide expert treatment closer to patients’ homes. We also operate commercial divisions that provide care to private patients in both London and the Middle East. With our academic partners at the UCL Institute of Ophthalmology, Moorfields is recognised as a leading centre of excellence in eye and vision research. Together we form one of the largest ophthalmic research sites in the world, with the largest patient population in Europe or the USA. We publish more scientific papers than any other eye and vision research site and have an extensive joint research portfolio.About UCL Institute of OphthalmologyThe UCL Institute of Ophthalmology is one of a number of specialised research centres within UCL (University College London) and is, together with Moorfields Eye Hospital, one of the leading centres for eye research worldwide. The combination of the institute’s research with the resources of Moorfields Eye Hospital opens the way for advances at the forefront of vision research. Close collaboration with other academic partners and with industry extends its impact. The institute has been named as the best place to study ophthalmology in the 2017 Centre for World University Rankings (CWUR). For further information, please visit www.ucl.ac.uk. Follow @ucleye on Twitter.About UCL (University College London)UCL is a diverse global community of world-class academics, students, industry links, external partners, and alumni. Our powerful collective of individuals and institutions work together to explore new possibilities.Since 1826, we have championed independent thought by attracting and nurturing the world’s best minds. Our community of more than 50,000 students from 150 countries and over 16,000 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems.The Times and Sunday Times University of the Year 2024, we are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact.We have a progressive and integrated approach to our teaching and research – championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors. For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge.We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today. We are UCL.www.ucl.ac.uk | Read news at www.ucl.ac.uk/news/ | Follow UCL News on Bluesky and LinkedInAbout Topcon Healthcare, Inc.Topcon Healthcare, Inc. is part of Topcon Corporation, a leading provider of digital healthcare solutions. Our vision is to improve access and quality of healthcare while decreasing the cost of care. To achieve this vision, we created Healthcare from the Eye™, a connected care ecosystem using AI-powered disease detection and management applied to noninvasive retinal imaging.About the INSIGHT Health Data Research HubINSIGHT is the world’s largest ophthalmic imaging bioresource, with over 35 million eye images linked to clinical data. An NHS initiative led by Moorfields in partnership with University Hospitals Birmingham, INSIGHT makes routinely collected patient eye data available for approved research that could lead to improvements in diagnosis, care and treatment of eye diseases, as well as systemic disease such as stroke and Alzheimer’s. INSIGHT’s mission is to improve healthcare by making it simpler for researchers to use large, anonymised sets of patient data in a safe and ethical way.
-
EYE-GO Secures Strategic Investment from Topcon Healthcare to Drive the Future of Connected Eye Care
COPENHAGEN, DENMARK & LA JOLLA, CA, USA — EYE-GO, a pioneering Danish MedTech company specializing in next-generation ophthalmic drug delivery, today announced a strategic investment from Topcon Healthcare, Inc., a global leader in robotic diagnostics and digital health solutions. This partnership aligns with Topcon Healthcare’s mission to improve access to high-quality eye care while reducing overall healthcare costs. The collaboration reflects a shared vision to revolutionize chronic eye disease management by integrating drug delivery, real-world adherence data, and diagnostic insights into a single, connected care pathway.“We are thrilled to welcome Topcon Healthcare as a strategic investor and partner,” said Christian Stig Møller, Chairman of EYE-GO. “In Topcon Healthcare, we’ve found not only a leading force in eyecare technology, but also a visionary partner in the digital health space. This strategic partnership also strengthens the EYE-GO board of directors with the appointment of Ali Tafreshi, Topcon Healthcare, Inc. CEO & President, and Robert N. Weinreb, MD, Distinguished Professor of Ophthalmology, University of California, San Diego.”This partnership will accelerate the development of the MistGo® Digital – a first-in-class microdosing drug delivery system combined with a digital adherence monitoring platform. The system reminds patients to administer their medication, verifies correct usage, and transmits real-time adherence data to clinicians. By combining precision drug delivery with intelligent monitoring, MistGo Digital closes the critical gap between prescription, administration, and compliance.“MistGo Digital is a breakthrough in ophthalmic therapy—bridging the gap between prescription and practice,” said Henrik Nagel, CEO of EYE-GO. “Topcon Healthcare’s involvement validates our approach and brings strategic synergy that will help realize our vision of fully connected eye care – from diagnostics to ongoing therapy management.”As a part of the collaboration, MistGo Digital will be integrated into Topcon Healthcare’s Harmony® digital health information platform. This integration will enable clinicians to link adherence and administration data with imaging results and disease progression, fostering earlier interventions and highly personalized care strategies.“Digital technology is transforming eye care, and MistGo Digital represents a leap forward in how therapies are delivered and monitored,” said Ali Tafreshi, CEO of Topcon Healthcare, Inc. “EYE-GO’s innovation complements our vision of connected care pathways. Adding an intelligent therapeutic solution enhances the patient experience, improves outcomes, and supports a more data-driven future for eye care.”This strategic partnership places both companies at the forefront of a growing movement toward connected health in eye care – where smart devices, data insights, and remote monitoring work together to optimize clinical care and elevate patient outcomes.About EYE-GO A/SEYE-GO is a MedTech innovation company dedicated to improving outcomes in eye health through advanced ophthalmic drug delivery. Its flagship solution, MistGo®, eliminates the complexity of traditional eye drops and is now evolving into MistGo Digital – the first connected platform that enables both reminder functionality and confirmation of medication use, providing valuable insight to patients, caregivers, and clinicians alike.In a recently conducted user survey¹ with the flagship solution, MistGo®, 20 out of 22 respondents expressed a preference for MistGo® over traditional eye drop bottles.¹ Manuscript in preparation; not yet peer-reviewed or publishedAbout Topcon Healthcare, Inc.Topcon Healthcare, Inc. is part of Topcon Corporation (TSE 7732). We are a leading provider of digital healthcare solutions whose vision is to improve access and quality of healthcare while decreasing the cost of care. To achieve this vision, we created Healthcare from the Eye™, the strategy of applying AI models to imaging data from the eye to facilitate earlier detection and better management of disease. Healthcare from the Eye is powered by Harmony®, a cloud-based, vendor-inclusive digital health information platform enabling a connected care ecosystem.
